(Q43108443)

14 November 2017

The 2008 Okuda lecture: Management of hepatocellular carcinoma: from surveillance to molecular targeted therapy (English)

1 reference

14 November 2017

hepatocellular carcinoma

1 reference

1

1 reference

14 November 2017

1 March 2010

1 reference

Journal of Gastroenterology and Hepatology

14 November 2017

1 reference

14 November 2017

25

1 reference

14 November 2017

3

1 reference

14 November 2017

439-452

1 reference

Hepatocellular carcinoma in cirrhosis: incidence and risk factors

14 November 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2009.06207.X

Development of evidence-based clinical guidelines for the diagnosis and treatment of hepatocellular carcinoma in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2009.06207.X

Management of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2009.06207.X

Report of the 17th Nationwide Follow-up Survey of Primary Liver Cancer in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2009.06207.X

Screening in liver disease: report of an AASLD clinical workshop

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2009.06207.X

Screening tests for hepatocellular carcinoma in patients with chronic hepatitis C: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2009.06207.X

Des-gamma-carboxy prothrombin as a useful predisposing factor for the development of portal venous invasion in patients with hepatocellular carcinoma: a prospective analysis of 227 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2009.06207.X

Serum human telomerase reverse transcriptase messenger RNA as a novel tumor marker for hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2009.06207.X

Differential diagnosis of nodular lesions in cirrhotic liver by post-vascular phase contrast-enhanced US with Levovist: comparison with superparamagnetic iron oxide magnetic resonance images.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2009.06207.X

Evaluation of posttreatment response of hepatocellular carcinoma with contrast-enhanced coded phase-inversion harmonic US: comparison with dynamic CT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2009.06207.X

Contrast harmonic sonography-guided radiofrequency ablation therapy versus B-mode sonography in hepatocellular carcinoma: prospective randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2009.06207.X

Response evaluation of transcatheter arterial chemoembolization in hepatocellular carcinomas: the usefulness of sonazoid-enhanced harmonic sonography

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2009.06207.X

Expression of OATP1B3 determines uptake of Gd-EOB-DTPA in hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2009.06207.X

Abc protein transport of MRI contrast agents in canalicular rat liver plasma vesicles and yeast vacuoles.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2009.06207.X

Pathologic diagnosis of early hepatocellular carcinoma: a report of the international consensus group for hepatocellular neoplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2009.06207.X

Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2009.06207.X

Prognosis of hepatocellular carcinoma: the BCLC staging classification

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2009.06207.X

Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2009.06207.X

Proposal of a new prognostic model for hepatocellular carcinoma: an analysis of 403 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2009.06207.X

Validation of a new prognostic staging system for hepatocellular carcinoma: a comparison of the biomarker-combined Japan Integrated Staging Score, the conventional Japan Integrated Staging Score and the BALAD Score

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2009.06207.X

Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: analysis of 48 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2009.06207.X

Combined intraarterial 5-fluorouracil and subcutaneous interferon-alpha therapy for advanced hepatocellular carcinoma with tumor thrombi in the major portal branches

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2009.06207.X

Combination therapy with S-1 and pegylated interferon alpha for advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2009.06207.X

Sorafenib in advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2009.06207.X

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2009.06207.X

Management of hepatocellular carcinoma in Japan: consensus-based clinical practice manual proposed by the Japan Society of Hepatology

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2009.06207.X

Hepatocellular carcinoma 2009 and beyond: from the surveillance to molecular targeted therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2009.06207.X

Imaging of Hepatocellular Carcinoma: Qualitative and Quantitative Analysis of Postvascular Phase Contrast-Enhanced Ultrasonography with Sonazoid

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2009.06207.X

Defect Reperfusion Imaging, a Newly Developed Novel Technology using Sonazoid in the Treatment of Hepatocellular Carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2009.06207.X

A proposal of novel treatment-assist technique for hepatocellular carcinoma in the Sonazoid-enhanced ultrasonography: value of defect re-perfusion imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2009.06207.X

Sonazoid-enhanced Ultrasound in the Diagnosis and Treatment of Hepatic Tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2009.06207.X

Sonazoid-Enhanced Ultrasonography for Diagnosis of Hepatic Malignancies: Comparison with Contrast-Enhanced CT

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2009.06207.X

Validation of a new prognostic staging system for hepatocellular carcinoma: The JIS score compared with the CLIP score

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2009.06207.X

Staging Hepatocellular Carcinoma by a Novel Scoring System (BALAD Score) Based on Serum Markers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2009.06207.X

Impact of Interferon Therapy after Curative Treatment of Hepatocellular Carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2009.06207.X

10.1111/J.1440-1746.2009.06207.X

21 January 2018

Identifiers

DOI

1 reference

14 November 2017

1 reference

PubMed ID

20370723